Title | Journal | Journal Categories | Citations | Publication Date |
---|---|---|---|---|
Erdafitinib in locally advanced or metastatic urothelial carcinoma | New England Journal of Medicine |
| 2019 | |
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants | European Urology |
| 140 | 2019 |
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability | European Urology |
| 104 | 2019 |
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors | European Urology |
| 173 | 2019 |
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells | Nature |
| 2,944 | 2018 |
Title | Journal | Journal Categories | Citations | Publication Date |
---|---|---|---|---|
Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes | Molecular Oncology |
| 2024 | |
Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial | The Journal of Pathology: Clinical Research |
| 2024 | |
A deep‐learning workflow to predict upper tract urothelial carcinoma protein‐based subtypes from H&E slides supporting the prioritization of patients for molecular testing | The Journal of Pathology: Clinical Research |
| 2024 | |
Chitinase 3‐like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder | Clinical & Translational Immunology |
| 2024 | |
Tumour tissue‐derived small extracellular vesicles reflect molecular subtypes of bladder cancer | Journal of Extracellular Vesicles |
| 2024 |